FFR in the Time of ISCHEMIA

The results of this great multicenter “real-life” registry are similar to those of randomized clinical trials that studied fractional flow reserve (FFR).

Lesion deferral based on FFR is a very safe strategy, even for lesions located in the proximal anterior descending artery.

Randomized controlled studies FAME and DEFER convincingly showed the safety of lesion revascularization deferral based on FFR. However, we needed a prospective full-scale real-world study to confirm it.

This came with the J-CONFIRM registry conducted by Dr. Shoichi Kuramitsu and colleagues, recently published in Circulation Cardiovascular Interventions.


Read also: EuroPCR 2018 | FAME 2: FFR Shows 5-Year Benefit for Hard Endpoints.


Prestigious researchers such as Dr. William Fearon (main author of the FAME trial) said that this real-world registry with a long-term follow-up finally closes our information breach and confirms in a definitive way the safety of FFR.

The J-CONFIRM registry included 1263 patients in 28 Japanese sites between 2013 and 2015.

All of them were assessed through FFR and revascularized according to its result.

At 2 years, the rate of target vessel failure (the primary study endpoint) was 5.5% in deferred lesions. Almost all of these events were revascularizations justified by clinically driven target vessel revascularization (5.2%), i.e., plaque progression. Cardiac deaths or infarctions related to deferred lesions were very infrequent during follow-up (0.42%), enough to determine that deferred lesions are not a safety concern.


Read also: Clinical Events after Deferral of LAD Treatment Guided by FFR or iFR.


Notably, events were conversely associated with FFR value: the lower the value of this measurement, the higher the risk of events at 2 years. This was particularly true with proximal lesions. FFR has a cutoff value, but it is not a binary variable at all: it is a continuous variable.

Independent predictors of events in deferred lesions were baseline FFR value (observing it as a continuous variable), left main coronary artery lesions, moderate to severe calcification, need for hemodialysis, or right coronary artery lesions. With these factors, lesions can still be deferred, but we should conduct a closer follow-up.

As an example of that, we could say that a patient with baseline FFR 0.81 will present a higher rate of events than a patient with FFR 0.95; however, both can be deferred safely. We would simply need to plan a closer clinical follow-up for the first patient.

Original Title: Two-year outcomes after deferral of revascularization based on fractional flow reserve: the J-CONFIRM registry.

Reference: Kuramitsu S et al. Circ Cardiovasc Interv. 2020;12:e008355.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...